Cushing's Syndrome Clinical Trial
Official title:
The Diagnostic Performance of Screening Tests for the Diagnosis of Cushing's Syndrome
Verified date | October 30, 2019 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will test the accuracy of screening tests for Cushing s syndrome in overweight
people with signs of the disorder. Cushing s syndrome is a rare disorder caused by excess
production of the hormone cortisol. Patients may have various problems, such as weight gain,
high blood pressure, diabetes, infections, mood problems, trouble concentrating, and
increased blood clotting. These symptoms are seen in many other disorders as well,
complicating the diagnosis. The reliability of tests currently used to diagnose Cushing s
syndrome is not known. To test their accuracy, subjects in this study who test positive for
Cushing s syndrome will be evaluated at NIH for 2 years to either confirm or refute the
laboratory results.
Patients between 18 and 75 years of age who are being treated at the George Washington
University Weight Management Program (GWUWMP) may participate in this study. Candidates will
be screened with a medical history, physical examination, measurement of body fat, blood
tests, and oral glucose tolerance test. They will also complete a symptoms checklist and
quality of life questionnaire.
Participants will be tested for Cushing s syndrome with a saliva collection, 24-hour urine
collection, and dexamethasone suppression test (DST). For the DST they will take 1 mg of
dexamethasone at night and report to GWUWMP the next morning for a blood draw. All specimens
blood, saliva, and urine will be tested for cortisol levels.
People whose test results are abnormal will be seen at the NIH outpatient clinic for a
medical history, physical examination, and blood tests; bedtime saliva collection; two
24-hour urine collections; and a 2-day 2-mg DST, followed by administration of
corticotropin-releasing hormone (CRH). CRH is a naturally occurring hormone that causes
cortisol levels to rise. Pre-treatment with dexamethasone prevents CRH from causing an
increase in cortisol in healthy people, but not in patients with Cushing s syndrome. For the
2-day DST, the subject takes 0.5 mg dexamethasone every 6 hours for eight doses. Two hours
after the last dose, CRH is injected through a catheter (thin plastic tube) inserted into an
arm vein. Blood is drawn just before giving CRH to measure dexamethasone and cortisol levels
and after giving CRH to measure cortisol levels.
People whose test results are normal will not be seen further at NIH. Those with high
cortisol levels will have repeat urine and saliva tests every 2 to 8 weeks for up to 24
months, and a 1-mg DST every 3 months during routine clinic visits at GWUWMP. People whose
increased cortisol is found to be due to another condition besides Cushing s syndrome will be
referred for evaluation and possible treatment. Those diagnosed with Cushing s syndrome will
have standard tests to identify the tumor causing the disorder, followed by standard medical
and surgical treatment.
Status | Completed |
Enrollment | 471 |
Est. completion date | October 30, 2019 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
- INCLUSION CRITERIA: Patients presenting for weight loss treatment at the GWUWMP Patients must have at least two of the signs and symptoms in Table 1 of the protocol, in addition to weight gain. If abdominal pain, backache and/or headache are present, only one of these symptoms can be used in any given patient, so that another feature must be present. Willing and able to be seen for up to 24 months Age 18-75 EXCLUSION CRITERIA: Weight more than 350 pounds, the maximum weight for radiologist examination tables necessary for the evaluation of Cushing's Syndrome Renal failure, creatinine greater than 2.6, because of possible effects on dexamethasone metabolism Pregnancy, because it alters interpretation of adrenal function tests Current use of oral, inhaled or intranasal glucocorticoids or use within 30 days of study Other significant medical disorders that may complicate participation or interpretation of the results. For example, a patient with a collagen vascular disorder who has taken intermittent high dose glucocorticoids, and might need to do this again, might not be offered participation. Use of black licorice or chewing tobacco within two weeks of the study or anticipated use during the study Use of phenytoin, barbiturate, loperamide or opiates within two weeks of the study or anticipated chronic use during the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
United States | GW University Medical Center GW Hospital Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab. 1999 Mar;84(3):878-82. — View Citation
Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism. 1979 Sep;28(9):955-77. Review. — View Citation
Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med. 1986 May 22;314(21):1329-35. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity and specificity of screening tests | Sensitivity and specificity of screening tests | months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02468193 -
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
|
Phase 2 | |
Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
Completed |
NCT00006278 -
Study of Cushing's Syndrome Not Related to ACTH Production
|
N/A | |
Completed |
NCT03606408 -
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
|
Phase 2 | |
Completed |
NCT02663609 -
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
|
||
Recruiting |
NCT01504555 -
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
|
Phase 3 | |
Active, not recruiting |
NCT00004343 -
Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome
|
N/A | |
Completed |
NCT02922257 -
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
|
||
Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
Terminated |
NCT00422201 -
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
|
Phase 2 | |
Completed |
NCT00001180 -
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
|
N/A | |
Completed |
NCT02804750 -
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
|
Phase 2 | |
Completed |
NCT00936741 -
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
|
Phase 3 | |
Recruiting |
NCT00004334 -
Study of Depression, Peptides, and Steroids in Cushing's Syndrome
|
N/A | |
Completed |
NCT03817840 -
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
|
||
Completed |
NCT01959711 -
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
|
Phase 4 | |
Completed |
NCT05633953 -
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
|
||
Completed |
NCT02889224 -
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
|
N/A | |
Terminated |
NCT00796783 -
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
|
N/A | |
Recruiting |
NCT02019706 -
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
|
Phase 2 |